Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)
A randomized head-to-head comparison of the 3 glycoprotein IIb/IIIa inhibitors during high-risk percutaneous coronary intervention is featured. The study shows that in the setting of less than 90% platelet inhibition, similar periprocedural enzyme release and 30-day major adverse cardiac events can...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2002-09, Vol.90 (5), p.526-529 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 529 |
|---|---|
| container_issue | 5 |
| container_start_page | 526 |
| container_title | The American journal of cardiology |
| container_volume | 90 |
| creator | Kini, Annapoorna S Richard, Merwin Suleman, Javed Perez, Nohelia Lee, Paul Fisher, Edward A Kamran, Mazullah Marmur, Jonathan D Sharma, Samin K |
| description | A randomized head-to-head comparison of the 3 glycoprotein IIb/IIIa inhibitors during high-risk percutaneous coronary intervention is featured. The study shows that in the setting of less than 90% platelet inhibition, similar periprocedural enzyme release and 30-day major adverse cardiac events can be accomplished regardless of the type of glycoprotein IIb/IIIa inhibitor used. |
| doi_str_mv | 10.1016/S0002-9149(02)02528-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72052503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914902025286</els_id><sourcerecordid>181103991</sourcerecordid><originalsourceid>FETCH-LOGICAL-e320t-e5c6f0a952d6c5bd36aa037471117d18184dbc9934e814feafca459f811bfe963</originalsourceid><addsrcrecordid>eNpdkl1rFTEQhhdRbK3-BCUIlRa6mo_9ypWUcvyAihfW65BNJjJlNzkm2eLxh_h7zfYcFbyaCXkymZn3rarnjL5mlHVvvlBKeS1ZI88oP6e85UPdPaiO2dDLmkkmHlbHf5Gj6klKt-XIWNs9ro4Y53RoWHdc_do4BybjHXhIiQRHMsbgcNT-gsA245pmtHBBtLdEjwZ_4KxHgp7M6HHGn-i_kXkXjI4W9UQ8mBgSJmKXuF5tIZolaw9hScSEGLyOu_I8QyyfZgyenN1sLj-RLU4hk5QXuzt_Wj1yekrw7BBPqq_vNjdXH-rrz-8_Xl1e1yA4zTW0pnNUy5bbzrSjFZ3WVPRNzxjrLRvY0NjRSCkaGFjjQDujm1a6gbHRgezESfVqX3cbw_cFUlYzJgPTtO9X9Zy2vKWigC__A2_DEn3pTXFBRSfksFZ7cYCWcQartrGsKu7Un3UX4PQA6GT05KL2BtM_TshVor5wb_cclNnvEKJKBsEbsBiLWsoGVIyq1Qjq3ghqVVmVeG8E1YnfJfGmVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230363986</pqid></control><display><type>article</type><title>Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kini, Annapoorna S ; Richard, Merwin ; Suleman, Javed ; Perez, Nohelia ; Lee, Paul ; Fisher, Edward A ; Kamran, Mazullah ; Marmur, Jonathan D ; Sharma, Samin K</creator><creatorcontrib>Kini, Annapoorna S ; Richard, Merwin ; Suleman, Javed ; Perez, Nohelia ; Lee, Paul ; Fisher, Edward A ; Kamran, Mazullah ; Marmur, Jonathan D ; Sharma, Samin K</creatorcontrib><description>A randomized head-to-head comparison of the 3 glycoprotein IIb/IIIa inhibitors during high-risk percutaneous coronary intervention is featured. The study shows that in the setting of less than 90% platelet inhibition, similar periprocedural enzyme release and 30-day major adverse cardiac events can be accomplished regardless of the type of glycoprotein IIb/IIIa inhibitor used.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(02)02528-6</identifier><identifier>PMID: 12208416</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Abciximab ; Aged ; Angioplasty, Balloon, Coronary - economics ; Antibodies, Monoclonal - economics ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Cardiac Catheterization - economics ; Cardiology ; Cardiomyopathies - pathology ; Clinical trials ; Combined Modality Therapy ; Creatine Kinase - blood ; Creatine Kinase, MB Form ; Diseases of the cardiovascular system ; Effectiveness ; Eptifibatide ; Female ; Heart ; Humans ; Immunoglobulin Fab Fragments - economics ; Immunoglobulin Fab Fragments - therapeutic use ; Incidence ; Isoenzymes - blood ; Male ; Medical procedures ; Medical sciences ; Middle Aged ; Myocardial Infarction - epidemiology ; Myocardial Infarction - therapy ; Necrosis ; Peptides - economics ; Peptides - therapeutic use ; Pilot Projects ; Platelet Aggregation Inhibitors - economics ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - economics ; Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use ; Predictive Value of Tests ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Stroke Volume - physiology ; Tirofiban ; Treatment Outcome ; Troponin I - blood ; Tyrosine - analogs & derivatives ; Tyrosine - economics ; Tyrosine - therapeutic use</subject><ispartof>The American journal of cardiology, 2002-09, Vol.90 (5), p.526-529</ispartof><rights>2002 Excerpta Medica Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Sep 1, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002914902025286$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13900117$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12208416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kini, Annapoorna S</creatorcontrib><creatorcontrib>Richard, Merwin</creatorcontrib><creatorcontrib>Suleman, Javed</creatorcontrib><creatorcontrib>Perez, Nohelia</creatorcontrib><creatorcontrib>Lee, Paul</creatorcontrib><creatorcontrib>Fisher, Edward A</creatorcontrib><creatorcontrib>Kamran, Mazullah</creatorcontrib><creatorcontrib>Marmur, Jonathan D</creatorcontrib><creatorcontrib>Sharma, Samin K</creatorcontrib><title>Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>A randomized head-to-head comparison of the 3 glycoprotein IIb/IIIa inhibitors during high-risk percutaneous coronary intervention is featured. The study shows that in the setting of less than 90% platelet inhibition, similar periprocedural enzyme release and 30-day major adverse cardiac events can be accomplished regardless of the type of glycoprotein IIb/IIIa inhibitor used.</description><subject>Abciximab</subject><subject>Aged</subject><subject>Angioplasty, Balloon, Coronary - economics</subject><subject>Antibodies, Monoclonal - economics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cardiac Catheterization - economics</subject><subject>Cardiology</subject><subject>Cardiomyopathies - pathology</subject><subject>Clinical trials</subject><subject>Combined Modality Therapy</subject><subject>Creatine Kinase - blood</subject><subject>Creatine Kinase, MB Form</subject><subject>Diseases of the cardiovascular system</subject><subject>Effectiveness</subject><subject>Eptifibatide</subject><subject>Female</subject><subject>Heart</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - economics</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Incidence</subject><subject>Isoenzymes - blood</subject><subject>Male</subject><subject>Medical procedures</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Myocardial Infarction - therapy</subject><subject>Necrosis</subject><subject>Peptides - economics</subject><subject>Peptides - therapeutic use</subject><subject>Pilot Projects</subject><subject>Platelet Aggregation Inhibitors - economics</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - economics</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Stroke Volume - physiology</subject><subject>Tirofiban</subject><subject>Treatment Outcome</subject><subject>Troponin I - blood</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - economics</subject><subject>Tyrosine - therapeutic use</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkl1rFTEQhhdRbK3-BCUIlRa6mo_9ypWUcvyAihfW65BNJjJlNzkm2eLxh_h7zfYcFbyaCXkymZn3rarnjL5mlHVvvlBKeS1ZI88oP6e85UPdPaiO2dDLmkkmHlbHf5Gj6klKt-XIWNs9ro4Y53RoWHdc_do4BybjHXhIiQRHMsbgcNT-gsA245pmtHBBtLdEjwZ_4KxHgp7M6HHGn-i_kXkXjI4W9UQ8mBgSJmKXuF5tIZolaw9hScSEGLyOu_I8QyyfZgyenN1sLj-RLU4hk5QXuzt_Wj1yekrw7BBPqq_vNjdXH-rrz-8_Xl1e1yA4zTW0pnNUy5bbzrSjFZ3WVPRNzxjrLRvY0NjRSCkaGFjjQDujm1a6gbHRgezESfVqX3cbw_cFUlYzJgPTtO9X9Zy2vKWigC__A2_DEn3pTXFBRSfksFZ7cYCWcQartrGsKu7Un3UX4PQA6GT05KL2BtM_TshVor5wb_cclNnvEKJKBsEbsBiLWsoGVIyq1Qjq3ghqVVmVeG8E1YnfJfGmVQ</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Kini, Annapoorna S</creator><creator>Richard, Merwin</creator><creator>Suleman, Javed</creator><creator>Perez, Nohelia</creator><creator>Lee, Paul</creator><creator>Fisher, Edward A</creator><creator>Kamran, Mazullah</creator><creator>Marmur, Jonathan D</creator><creator>Sharma, Samin K</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20020901</creationdate><title>Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)</title><author>Kini, Annapoorna S ; Richard, Merwin ; Suleman, Javed ; Perez, Nohelia ; Lee, Paul ; Fisher, Edward A ; Kamran, Mazullah ; Marmur, Jonathan D ; Sharma, Samin K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e320t-e5c6f0a952d6c5bd36aa037471117d18184dbc9934e814feafca459f811bfe963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Abciximab</topic><topic>Aged</topic><topic>Angioplasty, Balloon, Coronary - economics</topic><topic>Antibodies, Monoclonal - economics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cardiac Catheterization - economics</topic><topic>Cardiology</topic><topic>Cardiomyopathies - pathology</topic><topic>Clinical trials</topic><topic>Combined Modality Therapy</topic><topic>Creatine Kinase - blood</topic><topic>Creatine Kinase, MB Form</topic><topic>Diseases of the cardiovascular system</topic><topic>Effectiveness</topic><topic>Eptifibatide</topic><topic>Female</topic><topic>Heart</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - economics</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Incidence</topic><topic>Isoenzymes - blood</topic><topic>Male</topic><topic>Medical procedures</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Myocardial Infarction - therapy</topic><topic>Necrosis</topic><topic>Peptides - economics</topic><topic>Peptides - therapeutic use</topic><topic>Pilot Projects</topic><topic>Platelet Aggregation Inhibitors - economics</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - economics</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Stroke Volume - physiology</topic><topic>Tirofiban</topic><topic>Treatment Outcome</topic><topic>Troponin I - blood</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - economics</topic><topic>Tyrosine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kini, Annapoorna S</creatorcontrib><creatorcontrib>Richard, Merwin</creatorcontrib><creatorcontrib>Suleman, Javed</creatorcontrib><creatorcontrib>Perez, Nohelia</creatorcontrib><creatorcontrib>Lee, Paul</creatorcontrib><creatorcontrib>Fisher, Edward A</creatorcontrib><creatorcontrib>Kamran, Mazullah</creatorcontrib><creatorcontrib>Marmur, Jonathan D</creatorcontrib><creatorcontrib>Sharma, Samin K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kini, Annapoorna S</au><au>Richard, Merwin</au><au>Suleman, Javed</au><au>Perez, Nohelia</au><au>Lee, Paul</au><au>Fisher, Edward A</au><au>Kamran, Mazullah</au><au>Marmur, Jonathan D</au><au>Sharma, Samin K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>90</volume><issue>5</issue><spage>526</spage><epage>529</epage><pages>526-529</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>A randomized head-to-head comparison of the 3 glycoprotein IIb/IIIa inhibitors during high-risk percutaneous coronary intervention is featured. The study shows that in the setting of less than 90% platelet inhibition, similar periprocedural enzyme release and 30-day major adverse cardiac events can be accomplished regardless of the type of glycoprotein IIb/IIIa inhibitor used.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12208416</pmid><doi>10.1016/S0002-9149(02)02528-6</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2002-09, Vol.90 (5), p.526-529 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72052503 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Abciximab Aged Angioplasty, Balloon, Coronary - economics Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Biological and medical sciences Cardiac Catheterization - economics Cardiology Cardiomyopathies - pathology Clinical trials Combined Modality Therapy Creatine Kinase - blood Creatine Kinase, MB Form Diseases of the cardiovascular system Effectiveness Eptifibatide Female Heart Humans Immunoglobulin Fab Fragments - economics Immunoglobulin Fab Fragments - therapeutic use Incidence Isoenzymes - blood Male Medical procedures Medical sciences Middle Aged Myocardial Infarction - epidemiology Myocardial Infarction - therapy Necrosis Peptides - economics Peptides - therapeutic use Pilot Projects Platelet Aggregation Inhibitors - economics Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - economics Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use Predictive Value of Tests Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Stroke Volume - physiology Tirofiban Treatment Outcome Troponin I - blood Tyrosine - analogs & derivatives Tyrosine - economics Tyrosine - therapeutic use |
| title | Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A31%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20tirofiban,%20eptifibatide,%20and%20abciximab%20in%20minimizing%20myocardial%20necrosis%20during%20percutaneous%20coronary%20intervention%20(TEAM%20pilot%20study)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Kini,%20Annapoorna%20S&rft.date=2002-09-01&rft.volume=90&rft.issue=5&rft.spage=526&rft.epage=529&rft.pages=526-529&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(02)02528-6&rft_dat=%3Cproquest_pubme%3E181103991%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230363986&rft_id=info:pmid/12208416&rft_els_id=S0002914902025286&rfr_iscdi=true |